ViroPharma Chooses Medidata Solutions as Its Standard for Global Clinical Trials Management



    Medidata Solutions, a global provider of electronic clinical data
    capture, management and reporting solutions, today announced that
    Medidata Rave(R) has been selected by ViroPharma Incorporated as its
    enterprise-wide e-clinical platform. After an extensive 10-vendor
    review process, ViroPharma chose Medidata Rave for the collection and
    management of clinical data for all global Phase I-III studies in the
    U.S., Sweden, Canada, Germany, Belgium and France.

    With a focus on the development and commercialization of products
    used by physician specialists in hospital settings to treat serious
    diseases, ViroPharma is recognized worldwide for the advancement of
    innovative products addressing unmet medical needs. Because ViroPharma
    conducts trials throughout North America and Europe, the company
    needed a clinical data management solution that could scale globally,
    while allowing investigators and monitors to manage and view data in
    real-time. ViroPharma also required a solution that would provide ease
    of study build and deployment with intuitive navigation for
    investigators worldwide.

    While ViroPharma had piloted electronic data capture (EDC)
    solutions for several years, in September 2005 the company began an
    evaluation of EDC vendors in order to standardize on one solution.
    After an initial review of proposals, six vendors underwent technical
    evaluations. From this group, ViroPharma selected four vendors to
    complete on-site evaluations.

    "In the end, we chose Medidata Rave as our standard because it
    best meets our needs through features such as a user-friendly
    interface and robust data management. We were also impressed with the
    clinical and technical expertise of Medidata's professional services
    personnel," said Patty Wolf, clinical data manager at ViroPharma.
    "Medidata Rave allows us to operate very efficiently with our clinical
    teams, and its ability to integrate with other applications should
    facilitate future improvements to our clinical trial processes."

    ViroPharma has implemented Medidata Rave for 15 trials to date and
    has forecasted its role in additional trials in 2007. Unlike other
    platforms, Rave allows users to work in different countries against a
    single, global, centrally-managed repository of clinical data -
    allowing for real-time electronic access of trial data. For
    investigators, this means reduced time entering in the case book per
    patient due to automatic query generation, and requires less storage
    space than paper case report forms.

    "ViroPharma's selection of Medidata Rave from a group of 10
    vendors speaks to the industry-leading ease of use, flexibility and
    completeness of our solution for investigators, monitors and data
    managers within any phase of a clinical trial," said Tarek Sherif, CEO
    of Medidata Solutions. "The selection of Medidata Rave as ViroPharma's
    standard for clinical trials management demonstrates our ability to
    scale our product and services to meet the needs of a global client.
    We look forward to working with ViroPharma as they continue to
    increase the value of their clinical research investments."

    About ViroPharma Incorporated

    ViroPharma Incorporated is a biopharmaceutical company dedicated
    to the development and commercialization of products that address
    serious diseases treated by physician specialists and in hospital
    settings. ViroPharma commercializes Vancocin(R), approved for oral
    administration for treatment of antibiotic-associated pseudomembranous
    colitis caused by Clostridium difficile and enterocolitis caused by
    Staphylococcus aureus, including methicillin- resistant strains (for
    prescribing information, please download the package insert at
    http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently
    focuses its drug development activities in viral diseases including
    cytomegalovirus (CMV) and hepatitis C (HCV). For more information on
    ViroPharma, visit the company's website at http://www.viropharma.com.

    About Medidata Solutions Worldwide

    Medidata Solutions helps the world's leading pharmaceutical,
    biotechnology, medical device and research organizations maximize the
    value of their clinical research investments. Innovative process
    design, technology and services streamline clinical trials by
    providing early visibility to reliable clinical data - the lifeblood
    of every research organization. Working with companies and
    institutions both large and small, Medidata Solutions helps clinical
    researchers safely accelerate the process of bringing life-enhancing
    treatments to market - on five continents and in more than 70
    countries. Medidata Solutions brings significant value to its broad
    client base with deep clinical experience and expertise in more than
    20 therapeutic areas, projects in Phase I, II, III, IV, registries and
    surveillance, and studies with thousands of investigators and
    tens-of-thousands of subjects. For more information, please visit
    www.mdsol.com.